期刊
ANTICANCER RESEARCH
卷 41, 期 4, 页码 2093-2100出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.14980
关键词
Key Words; Renin?angiotensin system inhibitors; non-small cell lung cancer; anti-programmed cell death 1; ligand-1 antibodies; immunotherapy
类别
The study suggests that the use of RASi in NSCLC patients treated with anti-PD-1/PD-L1 antibodies is associated with significantly longer progression-free survival (PFS) and may enhance the efficacy of the antibodies.
Background/Aim: The Renin?Angiotensin system (RAS) induces immunosuppression in the tumor microenvironment, and RAS inhibitors (RASi) improve the tumor immune microenvironment. We evaluated the impact of RASi on the efficacy anti-programmed cell death1/Ligand-1 (anti-PD-1/PD-L1) antibodies. Patients and Methods: This retrospective study analyzed non-small cell lung cancer (NSCLC) patients who received anti-PD-1/PDL1 antibodies monotherapy as second-or later-line treatment. We classified patients into those with or without use of RASi. Results: A total of 256 NSCLC patients were included and 37 patients used RASi. The median PFS of patients treated with RASi was significantly longer than that of patients treated without (HR=0.59, 95%CI=0.40-0.88). The median OS of patients treated with RASi tended to be longer than that of patients treated without (HR=0.71, 95%CI=0.45-1.11). Conclusion: The use of RASi was associated with a significantly longer PFS in NSCLC patients treated with anti-PD-1/PD-L1 antibodies. RASi use may enhance the efficacy of anti-PD-1/PD-L1 antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据